Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial 
Cancel anytime
- Chart
- Upturn Summary
- Highlights
- Valuation
- Analyst Ratings
Upturn AI SWOT - About
Adagio Medical Holdings, Inc Common Stock (ADGM)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- YEAR
- MONTH
- WEEK
Upturn Advisory Summary
04/22/2025: ADGM (1-star) is currently NOT-A-BUY. Pass it for now.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $0
1 Year Target Price $0
| 0 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -31.41% | Avg. Invested days 5 | Today’s Advisory PASS |
Upturn Star Rating | Upturn Advisory Performance  1.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 04/22/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 16.77M USD | Price to earnings Ratio - | 1Y Target Price - |
Price to earnings Ratio - | 1Y Target Price - | ||
Volume (30-day avg) - | Beta 0.04 | 52 Weeks Range 0.62 - 9.34 | Updated Date 06/16/2025 |
52 Weeks Range 0.62 - 9.34 | Updated Date 06/16/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -2.48 |
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin - | Operating Margin (TTM) -5822.92% |
Management Effectiveness
Return on Assets (TTM) -82.76% | Return on Equity (TTM) - |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 22385905 | Price to Sales(TTM) 29.11 |
Enterprise Value 22385905 | Price to Sales(TTM) 29.11 | ||
Enterprise Value to Revenue 370.25 | Enterprise Value to EBITDA - | Shares Outstanding 15381600 | Shares Floating 3170756 |
Shares Outstanding 15381600 | Shares Floating 3170756 | ||
Percent Insiders 0.29 | Percent Institutions 85.46 |
Analyst Ratings
Rating - | Target Price - | Buy - | Strong Buy - |
Buy - | Strong Buy - | ||
Hold - | Sell - | Strong Sell - | |
Strong Sell - |
Upturn AI SWOT
Adagio Medical Holdings, Inc Common Stock
Company Overview
History and Background
Adagio Medical Holdings, Inc. is focused on developing and commercializing innovative technologies for the treatment of atrial fibrillation (Afib). Founded in 2011, the company has focused on developing novel cryoablation technology for persistent Afib.
Core Business Areas
- Pulsed Field Ablation (PFA): Development and commercialization of PFA system for the treatment of cardiac arrhythmias, including persistent atrial fibrillation.
Leadership and Structure
Details are limited, however, Kurt Geiger is the current Chairman, President and CEO. The company is structured around research, development, clinical trials, and commercialization of its PFA technology.
Top Products and Market Share
Key Offerings
- iCLASu2122 PFA System: Adagio's flagship product is a pulsed field ablation system designed to treat persistent atrial fibrillation. Market share data is unavailable at this time due to newness of the company and it is also not publicly traded. Competitors include Medtronic (MDT), Johnson & Johnson (JNJ), and Boston Scientific (BSX).
Market Dynamics
Industry Overview
The electrophysiology market is growing, driven by an aging population and increasing prevalence of Afib. PFA is an emerging technology that aims to improve safety and efficacy compared to traditional ablation methods.
Positioning
Adagio Medical aims to be a leader in the PFA market, focusing on persistent Afib, which is a difficult-to-treat condition. Their advantage lies in the unique design and capabilities of their iCLAS system.
Total Addressable Market (TAM)
The global cardiac ablation market is projected to reach approximately $10 billion by 2028. Adagio is positioned to capture a significant share of the TAM with its PFA technology.
Upturn SWOT Analysis
Strengths
- Innovative PFA technology (iCLAS)
- Focus on persistent Afib
- Potential for improved safety and efficacy compared to traditional ablation
Weaknesses
- Limited commercialization experience
- Reliance on single product (iCLAS)
- Need for significant capital investment to scale operations
Opportunities
- Growing electrophysiology market
- Increasing adoption of PFA technology
- Potential for partnerships with larger medical device companies
Threats
- Competition from established medical device companies (Medtronic, J&J, Boston Scientific)
- Regulatory hurdles and clinical trial risks
- Risk of technological obsolescence
Competitors and Market Share
Key Competitors
- MDT
- JNJ
- BSX
Competitive Landscape
Adagio Medical competes with established players in the electrophysiology market. Its advantage lies in its innovative PFA technology, but it faces challenges in terms of scale and market access.
Growth Trajectory and Initiatives
Historical Growth: Limited historical data available as a private company.
Future Projections: Growth is expected to be driven by adoption of their iCLAS PFA system. Analyst estimates are unavailable due to it being a private company.
Recent Initiatives: Focus on clinical trials to demonstrate the safety and efficacy of the iCLAS system; securing regulatory approvals; building a commercial infrastructure to support launch.
Summary
Adagio Medical is a medical device company with a focus on atrial fibrillation. Its iCLAS PFA system is a promising technology, but it faces challenges in competing with larger, more established players. The company needs to successfully navigate clinical trials and regulatory hurdles to achieve commercial success. They are also going to need financial backing to continue in their efforts.
Peer Comparison
Sources and Disclaimers
Data Sources:
- Company Website
- Industry Reports
- Analyst Reports (limited availability)
Disclaimers:
This analysis is based on publicly available information and analyst assumptions. Actual results may vary. This is not financial advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Adagio Medical Holdings, Inc Common Stock
Exchange NASDAQ | Headquaters Laguna Hills, CA, United States | ||
IPO Launch date 2024-08-01 | CEO & Director Mr. Todd Usen | ||
Sector Healthcare | Industry Medical Devices | Full time employees 80 | Website https://adagiomedical.com |
Full time employees 80 | Website https://adagiomedical.com | ||
Adagio Medical Holdings, Inc., a developmental stage medical device company, focuses on the development and commercialization of ablation technologies for the treatment of cardiac arrhythmias. It offers treatment for cardiac arrhythmias, including atrial fibrillation, atrial flutter, and ventricular tachycardia. The company's product portfolio includes iCLAS atrial ultra-low temperature cryoablation (ULTC) catheter and accessories; vCLAS ventricular ULTC catheter; and Cryopulse atrial pulsed-field cryoablation catheter and accessories. Adagio Medical Holdings, Inc. was founded in 2011 and is headquartered in Laguna Hills, California.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.